DISULFIRAM

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category UNKNOWN
ATC N07BB01 P03AA04
UNII TR3MLJ1UAI
EPA CompTox DTXSID1021322

Structure

InChI Key AUZONCFQVSMFAP-UHFFFAOYSA-N
Smiles CCN(CC)C(=S)SSC(=S)N(CC)CC
InChI
InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C10H20N2S4
Molecular Weight 296.55
AlogP 3.62
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 4.0
Polar Surface Area 6.48
Molecular species None
Aromatic Rings 0.0
Heavy Atoms 16.0

Bioactivity

Mechanism of Action Action Reference
Aldehyde dehydrogenase inhibitor INHIBITOR Wikipedia DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- 360-1259 - - -
Enzyme Oxidoreductase
- 150 - - 0
Enzyme Protease Threonine protease Threonine protease PBT clan Threonine protease T1A subfamily
- - - - 92
Enzyme Transferase
- 600 - - -
Enzyme
- 600-1900 - - 0
Epigenetic regulator Eraser Lysine demethylase Jumonji domain-containing
- 10000 - - -
Epigenetic regulator Reader Plant homeodomain
- 10000 - - -
Epigenetic regulator Writer Protein methyltransferase
- 1600 - - -
Ion channel Voltage-gated ion channel Transient receptor potential channel
3000 - - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - -4-64
Unclassified protein
- 400 - - -
Assay Description Organism Bioactivity Reference
Inhibition of HIV-1 replication in a proliferating human T-cell line assayed using an XTT assay. Human immunodeficiency virus 1 3.2
Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate at 10 uM by liquid scintillation counting Homo sapiens 50.0 %
Antiproliferative activity against human MCF7 cells expressing BCA2 and estrogen receptor after 72 hrs by MTT assay Homo sapiens 100.0 nM
Antiproliferative activity against human MDA-MB-231 cells expressing BCA2 and ERalpha after 72 hrs by MTT assay Homo sapiens 320.0 nM
Antiproliferative activity against human T47D cells expressing BCA2 and estrogen receptor after 72 hrs by MTT assay Homo sapiens 170.0 nM
Cytotoxicity against human K562 cells expressing ALDH1 at 15 uM after 45 mins by flow cytometry based method Homo sapiens 17.26 %
Inhibition of ALDH1 in human K562 cells at 15 uM after 45 mins by flow cytometry based method relative to bodipy-aminoacetaldehyde Homo sapiens 57.26 %
PUBCHEM_BIOASSAY: High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media. (Class of assay: confirmatory) None 780.0 nM
PUBCHEM_BIOASSAY: High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor - Dose Response. (Class of assay: confirmatory) [Related pubchem assays: 1045, 1004, 824, 999, 818, 827, 823 ] None 87.0 nM
PUBCHEM_BIOASSAY: High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Casein Expression - Dose Response. (Class of assay: confirmatory) [Related pubchem assays: 1004, 824, 999, 818, 827, 823 ] None 91.0 nM
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) None 356.0 nM DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) None 201.0 nM
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) None 954.0 nM
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) None 368.0 nM
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting Homo sapiens 8.5 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens -3.8 %
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens 15.5 %
Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control Mus musculus 55.0 %
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 71.59 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 64.06 %
Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC Homo sapiens 0.0 %
PubChem BioAssay. Leishmania major promastigote EC50 determinations. (Class of assay: confirmatory) None 249.0 nM
Inhibition of chymotrypsin like activity of 20S proteasome (unknown origin) using suc-leu-leu-val-tyr-AMC as substrate at 10 uM after 40 mins in presence of 1 uM copper by fluorescence assay Homo sapiens 92.0 %
Inhibition of recombinant human N-terminal His6-tagged and C-terminal Strep-tagged MAGL expressed in Escherichia coli Rosetta using [3H]2-OG as substrate after 10 mins by liquid scintillation counting method Homo sapiens 360.0 nM
Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measured after 60 mins by MALDI-TOF MS analysis Homo sapiens 50.0 %
Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measured after 60 mins by MALDI-TOF MS analysis Homo sapiens 50.0 %
Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measured after 60 mins by MALDI-TOF MS analysis Homo sapiens 600.0 nM
Inhibition of recombinant human LOX expressed in HEK293 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method Homo sapiens 320.0 nM
Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method Homo sapiens 150.0 nM
Inhibition of recombinant human LOXL3 expressed in CHO cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method Homo sapiens 93.0 nM
Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method Homo sapiens 59.0 nM
Inhibition of recombinant human LOX expressed in HEK293 cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control Homo sapiens 40.0 %
Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control Homo sapiens 40.0 %
Inhibition of recombinant human LOXL3 expressed in CHO cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control Homo sapiens 40.0 %
Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control Homo sapiens 40.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 0.44 %
Inhibition of GSDMD in human monocyte/macrophages assessed as inhibition of pyroptosis in presence of Cu2+ Homo sapiens 400.0 nM
Inhibition of GSDMD in mouse monocyte/macrophages assessed as inhibition of pyroptosis in presence of Cu2+ Mus musculus 400.0 nM
Cytotoxicity against patient derived GSC after 96 hrs by CellTiter-Glo assay Homo sapiens 31.1 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 100.36 %
SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 220.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 7.16 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 7.16 %
Inhibition of human liver FBPase C38S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay Homo sapiens 600.0 nM
Inhibition of human liver FBPase C128S mutant expressed in Escherichia coli BL21 (DE3) at 1000 uM using FBP as substrate incubated for 5 mins by malachite green dye based assay relative to control Homo sapiens 50.0 %
Inhibition of Giardia lamblia carbamate Kinase preincubated for 15 mins followed by ADP and carbamate phosphate addition and measured after 20 mins by ATPLite reagent based luminescence assay Giardia intestinalis 600.0 nM
Antigiardial activity against Giardia lamblia incubated for 48 hrs by ATPLite reagent based luminescence assay Giardia intestinalis 900.0 nM
Inhibition of ALDH1A1 (unknown origin) Homo sapiens 130.0 nM
Inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase transfected in Escherichia coli BL21 (DE3) at 50 uM incubated for 3 mins in presence of NADH by spectrophotometric analysis relative to control Candida albicans 82.97 %

Cross References

Resources Reference
ChEBI 4659
ChEMBL CHEMBL964
DrugBank DB00822
DrugCentral 928
FDA SRS TR3MLJ1UAI
Human Metabolome Database HMDB0014960
Guide to Pharmacology 7168
KEGG C01692
PharmGKB PA449376
PubChem 3117
SureChEMBL SCHEMBL27213
ZINC ZINC000001529266
CONTENTS